First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [31] The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 16 - 27
  • [32] Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
    Mamiya, H.
    Tahara, R. K.
    Tolaney, S. M.
    Choudhry, N. K.
    Najafzadeh, M.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1825 - 1831
  • [33] Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2-locally advanced or metastatic breast cancer: a Brazilian private payer perspective
    Buehler, Anna Maria
    Castilho, Gabriela
    Dionne, Pierre-Alexandre
    Stefani, Stephen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [34] Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR plus early-stage breast cancer
    Lipsitz, Michael
    Delea, Thomas E.
    Guo, Amy
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (10) : 2315 - 2328
  • [35] First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
    Di Leo, Angelo
    Jerusalem, Guy
    Torres, Roberto
    Verhoeven, Didier
    Pendergrass, Kelly
    Malorni, Luca
    Lichfield, Jasmine
    Martin, Miguel
    BREAST, 2018, 38 : 144 - 149
  • [36] Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
    Butani, Dimple
    Gupta, Nidhi
    Jyani, Gaurav
    Bahuguna, Pankaj
    Kapoor, Rakesh
    Prinja, Shankar
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 625 - 640
  • [37] Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer
    Delea, Thomas E.
    Hawkes, Carol
    Amonkar, Mayur M.
    Lykopoulos, Konstantinos
    Johnston, Stephen R. D.
    BREAST CARE, 2013, 8 (06) : 429 - 437
  • [38] Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer
    Bundred, N
    CANCER INVESTIGATION, 2005, 23 (02) : 173 - 181
  • [39] Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan
    Lertjanyakun, Verin
    Chaiyakunapruk, Nathorn
    Kunisawa, Susumu
    Imanaka, Yuichi
    PHARMACOECONOMICS, 2018, 36 (09) : 1113 - 1124
  • [40] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
12345